Vision Sensing Acquisition Corp., a special purpose acquisition company, has formally entered into a definitive Agreement and Plan of Merger with Mediforum, a prominent biotechnology firm based in Korea. The proposed merger aims to make Mediforum a publicly listed company upon completion, and the combined entity is expected to be listed on NASDAQ with a new ticker symbol, "Mediforum."

Mediforum, a leading biotechnology company in Korea, is known globally for its ethical drug research, diagnostic reagents, and strategic application products. Founded by accomplished researchers, the company is dedicated to advancing biomedical sciences with a mission to improve the quality of life for individuals dealing with conditions such as Alzheimer's disease (AD) and neuropathic pain.

The company's diverse portfolio includes anti-dementia medications and health functional foods, positioning Mediforum at the forefront of biomedical innovation. Their flagship product, PM012, is currently undergoing Phase 2b clinical trials for AD, with plans for subsequent Phase 3 trials in both Korea and the U.S. Additionally, PM012 is exploring indications for Parkinson’s disease (PD) and stroke, showcasing its potential to address a range of neurological challenges. The evaluation for diabetic peripheral neuropathy (DPN) positions MF018 as a versatile solution in neuropathic conditions.

A significant milestone for Mediforum is its status as the first Korean biotech entity to list on NASDAQ, establishing itself as a global industry leader. The company's corporate culture, centered on technology, innovation, and leadership, highlights its dedication to transformative healthcare solutions.

Source: globenewswire.com

 

 

 

Report Abuse